Phillip Monk

Chief Scientific Officer (CSO) @SynairgenPLC. All views are my own.

[Phillip Monk @PhillMonk]

@ESWInfluenza @linfa_wang @dukenus @lwazimanzi @_AfricanUnion @hurt_lab @Roche @IHEID Looking forward to attending the @ESWIinfluenza #ESWIsummit this week in Brussels on behalf of @Synairgenplc

[ESWI @ESWInfluenza]

#eswisummit 21 June Brussels 📢Last🪑available!
Experts panel views on #pandemic #preparedness with @linfa_wang @dukenus @lwazimanzi @_AfricanUnion @hurt_lab @Roche and Prof. Gian-Luca Burci @IHEID
Check out the speaker lineup 🔎
https://t.co/aPFz0Fr0Ew

[Phillip Monk @PhillMonk]

Nice data, interferon beta versus the SARS-CoV-2 Delta variant. https://t.co/bt21xojXxU

#covid19research

[Phillip Monk @PhillMonk]

Great news from our clinical team today as we hit our 610 randomised patient target in the SPRINTER Phase 3 trial. We look forward to seeing #SNG001’s impact in hospitalised settings.

[Synairgen @Synairgenplc]

We are pleased to announce completion of patient recruitment in our global Phase 3 SPRINTER trial for #SNG001. With the randomisation of our 610th patient, we are one step closer to understanding the potential of SNG001 in the global #COVID battle.

https://t.co/15wrSFipLb

[Phillip Monk @PhillMonk]

ACTG Announces Graduation of Investigational Inhaled COVID-19 Treatment to Phase 3 Study in ACTIV-2 – ACTG Network https://t.co/Yjxx6EeRPW

[Phillip Monk @PhillMonk]

@LancetRespirMed As the authors point out these results for injected IFN-beta cannot be extrapolated to other routes of administration, e.g. inhaled. Phase 3 results from multinational 610 patient SPRINTER trial of inhaled IFN-beta in hospitalised #COVID19 patients expected early 2022. #synairgen

[Phillip Monk @PhillMonk]

This is exciting news coming from the #ACTIV2 trial in the US and we look forward to continuing our work with the NIAID team as #SNG001 progresses into Phase 3.

[Synairgen @Synairgenplc]

We are pleased to share that #SNG001, our investigational inhaled interferon beta, is advancing to Phase 3 in the NIH-sponsored #ACTIV2 COVID-19 trial. You can read the full announcement here: https://t.co/oPer057K7R